DOI:
10.1055/s-00000071
Seminars in Neurology
LinksClose Window
References
Taal W, Oosterkamp HM, Walenkamp AM. , et al.
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Lancet Oncol 2014;
15 (09) 943-953
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.